UK markets open in 2 hours 6 minutes
NIKKEI 225
26,390.00 +216.02 (+0.83%) HANG SENG
17,466.89 +216.01 (+1.25%) CRUDE OIL
81.86 -0.29 (-0.35%) GOLD FUTURES
1,662.20 -7.80 (-0.47%) DOW
29,683.74 +548.75 (+1.88%) BTC-GBP
18,096.62 +645.95 (+3.70%)
Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 108.33 |
| Open | 110.11 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's range | 108.93 - 111.00 |
| 52-week range | 61.28 - 120.23 |
| Volume | |
| Avg. volume | 1,119,249 |
| Market cap | 9.625B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.28 |
| Earnings date | 01 Nov 2022 - 07 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 130.74 |
- Zacks
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
- Simply Wall St.
Investors bid Sarepta Therapeutics (NASDAQ:SRPT) up US$793m despite increasing losses YoY, taking five-year CAGR to 21%
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
- Zacks
Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA
The FDA lifts the clinical hold placed on Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, being evaluated in the ongoing phase II MOMENTUM study.
© 2022 Yahoo. All rights reserved.
